Underlining the importance of targeting this pathway to prevent or delay the most aggressive forms of PrCa, the U.S. Food and Drug Administration has recently approved olaparib, a PARP1 inhibitor [63], for the treatment of metastatic CRPrCa. This evidence concerns the gene PARP1 and pure red-cell aplasia.